SKYRIZI HAS **~99% PREFERRED* NATIONAL COMMERCIAL AND MEDICARE PART D COVERAGE IN Ps & PsA²**

COMMERCIAL

MEDICARE PART D

~99^%

PREFERRED COVERAGE²*^†

97^%

PREFERRED COVERAGE²*^†

National commercial and Medicare Part D formulary coverage under the pharmacy benefit as of August 2025.

*SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.

^†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

^‡Advanced systemics inclusive of phosphodiesterase-4 (PDE4) inhibitors, Janus kinase (JAK) inhibitors, or biologics.

^IIBased on paid commercial claims data from national data providers for a filled SKYRIZI prescription for Ps or PsA for the period February 2025 through January 2025, inclusive of savings card redemptions.

PREFERRED COVERAGE MEANS
SKYRIZI IS AVAILABLE:

With no advanced systemic failure required^‡
At the lowest branded copay/coinsurance
tier

91^%

OF COMMERCIAL CLAIMS FOR A  FILLED SKYRIZI PRESCRIPTION  COST PATIENTS $0-$5^3§II

^§Patients' actual out-of-pocket costs may vary depending on their insurance coverage and eligibility for support programs.

^IIBased on paid commercial claims data from national data providers for a filled SKYRIZI prescription for Ps or PsA for the period January 2023 through September 2023, inclusive of savings card redemptions.

MEDICARE PART D REDESIGN

In 2025, annual out-of-pocket costs will be capped at $2,000 for people with Medicare Part D.⁴

ENROLL YOUR PATIENTS IN COMPLETE TODAY

PLANS LISTING SKYRIZI AS PREFERRED* FOR Ps IN YOUR COUNTY

SEE WHICH PLANS IN YOUR AREA INCLUDE SKYRIZI ON THEIR PREFERRED DRUG FORMULARY

Select a filter

Please enter a valid zip code.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coverage requirements and benefits designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies. The health plans and/or pharmacy benefit managers listed here have not endorsed and are not affiliated with this material.

Local can include national, regional, state, State Medicaid, and Managed Medicaid plans within the given geography.

BRIDGE PROGRAM ELIGIBILITY

No-cost product available for eligible patients in the event of denial in coverage
due to step-therapy requirement^¶

PRESCRIBED BRANDED SYSTEMIC
BY DERMATOLOGISTS FOR PATIENTS
WITH PSORIATIC DISEASE

Based on combined prescription data across
Ps and PsA, excluding generics and OTC

Source of data: Integrated Symphony Health as of 3/2024.⁵ The term branded systemic is defined as systemic drugs
that are sold by a specific name or trademark and protected by patent. OTC stands for over-the-counter medications.

ENCOURAGE YOUR PATIENTS TO ENROLL IN

AFFORDABILITY

Eligible, commercially insured patients may pay as little as $0 per quarterly dose^#

ACCESS SUPPORT

Field Reimbursement Managers are in-person or virtual resources who can address access-related questions. They can provide education on access, reimbursement, payer policies, and case-specific support

BRIDGING PATIENTS

No charge for eligible patients experiencing initial insurance denial for up to 24 months^¶

^¶Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI® (risankizumab-rzaa) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

^#Eligibility: Available to patients with commercial insurance coverage for SKYRIZI® (risankizumab-rzaa) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit SKYRIZISavingsCard.com or call 1.866.SKYRIZI for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy

STAY UP TO DATE ON THE LATEST SKYRIZI NEWS AND INFORMATION